WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins and plasmid DNA (pDNA).
The worldwide market for microbial-derived products and intermediates is experiencing rapid growth, fuelled by the demand for complex biomolecules.
Go deeper with GlobalData
These include nanobodies, enzymes, antibody fragments, cytokines, pDNA, antigens and polypeptides, which are crucial for therapy development.
WuXi Bio noted that to overcome the complexities associated with these smaller biomolecules’ production, its platform facilitates the development and production of microbial-derived biologics, ensuring high yield quality, stability and scaleability.
The platform can achieve titers [a measurement of the amount or concentration of a substance in a solution] of more than 15 g/L for non-monoclonal antibody (mAb) recombinant proteins and more than 1 g/L for pDNA.
It expedites the biotherapeutic advancement for worldwide partners by providing streamlined processes that cater to a wide variety of project needs, from research to commercial manufacturing.
It also delivers a comprehensive and cost-effective chemistry, manufacturing and controls (CMC) strategy.
As part of WuXi Biologics’ integrated technology offerings, which are based on microbial expression systems, the platform includes early-stage research, good manufacturing practice (GMP) and CMC development.
WuXi Biologics CEO Dr Chris Chen stated: “We are excited to upgrade our microbial solutions with the innovative EffiX platform, which offers our clients exceptional productivity and product quality, along with scaleability and flexibility at every stage of development.
“WuXi Biologics’ continual launching of new technology platforms stems from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to accelerate the delivery of more high-quality and affordable biologics to patients worldwide.”
In August 2024, WuXi Biologics partnered with Medigene to focus on the development of TCR-guided T-cell engagers for the treatment of difficult-to-treat tumours.
